Ata Ppgl Medical Treatment Initiation

---
name: ata-ppgl-medical-treatment-initiation
description: Initiates and adjusts medical treatment for functional pheochromocytoma and paraganglioma. Starts with selective α-blocker for catecholamine excess hypertension or symptoms, adds calcium antagonists or metyrosine if BP control insufficient, and adds β-blockers only after adequate α-blockade for tachycardia/tachyarrhythmia, myocardial damage, heart failure, or ischemic heart disease.
---

# Initiate and adjust medical treatment for functional pheochromocytoma and paraganglioma

## STEP 1 — Gather Information
Confirm biochemical evidence of functional PPGL (elevated fractionated metanephrines or catecholamines in 24h urine/plasma) and assess for hypertension/symptoms (headache, palpitations, sweating). Document current BP, heart rate, and presence of cardiac comorbidities (tachycardia, heart failure, ischemic heart disease). Note current α-blocker dose if already initiated.

## STEP 2 — Rule In / Rule Out
Rule in: Biochemical confirmation of functional PPGL with hypertension or symptoms → proceed to STEP 3.
Rule out: Non-functional PPGL (normal biochemical markers) → do not initiate α-blockade for medical management (consider preoperative blockade only if surgery planned after comprehensive evaluation).

## STEP 3 — Classify or Stratify
Classify BP control status on current α-blocker therapy:
  - Controlled (sitting BP <130/80 mmHg): proceed to assess β-blocker indication.
  - Not controlled: need to intensify BP control.

## STEP 4 — Decide
If not controlled: add calcium antagonist (e.g., amlodipine 5 mg daily) or metyrosine (start 0.5 g/day, titrate to 2-3 g/day) to achieve BP target.
If controlled: add β-blocker (e.g., atenolol 25 mg daily) only if tachycardia/tachyarrhythmia, myocardial damage, heart failure, or ischemic heart disease is present; otherwise, continue current α-blocker therapy.

## Clinical Guardrails / Mimics / Pitfalls
Never administer β-blocker before adequate α-blockade (risk of hypertensive crisis). Orthostatic hypotension common with first dose → administer at bedtime. Monitor for drowsiness, insomnia, anxiety. If using metyrosine, encourage ≥2 L/day water to prevent crystalluria. Do not use nonselective α-blockers (e.g., phenoxybenzamine) as first choice due to substantial β-blocking effects risking hypertensive attacks.

## Concrete Clinical Example
45yo with functional PPGL (urinary metanephrines 3x ULN), episodic HTN (160/100), headaches. Start prazosin 1 mg HS. Titrate to 5 mg BID → BP 140/85, HR 105. BP not controlled → add amlodipine 5 mg daily. BP 125/78, HR 95. BP controlled but HR elevated; no cardiac comorbidities → continue current therapy. If HR remained >100 with symptoms after adequate α-blockade, add atenolol 25 mg daily.

**Source:** Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma, Japan Endocrine Society, 2025, 10.1507/endocrj.EJ25-0165